Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: 5-year outcomes of NSABP protocol B-41.

被引：17
|
作者：
Robidoux, Andre
Tang, Gong
Rastogi, Priya
Geyer, Charles E.
Azar, Catherine A.
Atkins, James Norman
Fehrenbacher, Louis
Bear, Harry Douglas
Baez-Diaz, Luis
Sarwar, Shakir
Margolese, Richard G.
Farrar, William Blair
Brufsky, Adam M.
Shibata, Henry R.
Bandos, Hanna
Paik, Soonmyung
Costantino, Joseph P.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
机构：
[1] NSABP NRG Oncol, Montreal, PQ, Canada
[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[3] NRG Oncol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] NSABP NRG Oncol, Pittsburgh, PA USA
[6] Univ Pittsburgh Med Canc Ctr, Magee Womens Hosp, Pittsburgh, PA USA
[7] Virginia Commonwealth Univ, Massey Canc Ctr, Pittsburgh, PA USA
[8] NSABP NRG Oncol, Green Valley, AZ USA
[9] Kaiser Permanente, Green Valley, AZ USA
[10] NSABP NRG Oncol, Goldsboro, NC USA
[11] Southeastern Med Oncol Ctr, Goldsboro, NC USA
[12] NSABP NRG Oncol, Novato, CA USA
[13] Kaiser Permanente Northern Calif, Novato, CA USA
[14] NRG Oncol, Richmond, VA USA
[15] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[16] NSABP NRG Oncol, San Juan, PR USA
[17] San Juan CCOP, San Juan, PR USA
[18] NSABP NRG Oncol, Columbus, OH USA
[19] Columbus NCORP Grant Med Ctr, Columbus, OH USA
[20] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[21] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[22] UPMC, Magee Womens Hosp, Pittsburgh, PA USA
[23] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada
[24] Severance BioMed Sci Inst, Pittsburgh, PA USA
[25] Yonsei Univ, Coll Med, Pittsburgh, PA USA
[26] NSABP NRG Oncol, Washington, DC USA
[27] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA
[28] NSABP NRG Oncol, Orlando, FL USA
[29] Orlando Hlth, UF Canc Ctr, Orlando, FL USA
[30] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501
引用
收藏
页数：2
相关论文
共 36 条
  • [31] Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
    Martin, Miguel
    Holmes, Frankie A.
    Ejlertsen, Bent
    Delaloge, Suzette
    Moy, Beverly
    Iwata, Hiroji
    von Minckwitz, Gunter
    Chia, Stephen K. L.
    Mansi, Janine
    Barrios, Carlos H.
    Gnant, Michael
    Tomasevic, Zorica
    Denduluri, Neelima
    Separovic, Robert
    Gokmen, Erhan
    Bashford, Anna
    Borrego, Manuel Ruiz
    Kim, Sung-Bae
    Jakobsen, Erik Hugger
    Ciceniene, Audrone
    Inoue, Kenichi
    Overkamp, Friedrich
    Heijns, Joan B.
    Armstrong, Anne C.
    Link, John S.
    Joy, Anil Abraham
    Bryce, Richard
    Wong, Alvin
    Moran, Susan
    Yao, Bin
    Xu, Feng
    Auerbach, Alan
    Buyse, Marc
    Chan, Arlene
    LANCET ONCOLOGY, 2017, 18 (12): : 1688 - 1700
  • [32] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
    Zhang, Qingyuan
    Shen, Kunwei
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne W. Y.
    Tang, Jinhai
    Jiang, Zefei
    Tseng, Ling-Ming
    Wang, Xiaojia
    Yang, Liu
    Qian, Chenxi
    Shao, Zhimin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [33] NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+BREAST CANCER: 5-YEAR INTERIM ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET).
    Martin, Miguel
    Buyse, Marc
    Devoto, Jeannette
    Xu, Feng
    Wong, Alvin
    Chan, Arlene
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [34] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
    Rastogi, Priya
    O'Shaughnessy, Joyce
    Martin, Miguel
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Goetz, Matthew P.
    Hamilton, Erika P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Tryakin, Alexey
    Cicin, Irfan
    Testa, Laura
    Neven, Patrick
    Huober, Jens
    Shao, Zhimin
    Wei, Ran
    Andre, Valerie
    Munoz, Maria
    San Antonio, Belen
    Shahir, Ashwin
    Harbeck, Nadia
    Johnston, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 987 - 993
  • [35] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 42, 10.1200/JCO.23.01994, 2024)
    Rastogi, Priya
    O'Shaughnessy, Joyce
    Martin, Miguel
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Goetz, Matthew P.
    Hamilton, Erika P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Tryakin, Alexey
    Cicin, Irfan
    Testa, Laura
    Neven, Patrick
    Huober, Jens
    Shao, Zhimin
    Wei, Ran
    Andre, Valerie
    Munoz, Maria
    San Antonio, Belen
    Shahir, Ashwin
    Harbeck, Nadia
    Johnston, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2111 - 2111
  • [36] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 43, 10.1200/JCO-24-02469, 2024)
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01) : 113 - 113
1234